Cocrystal Pharma $6.9 million arbitration case against HVIVO2 Apr 2026 10:17
The following was released yesterday by Cocrystal Pharma.
"In December 2023 we received authorization from the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) to conduct a Phase 2a human challenge study with oral CC-42344 as a potential treatment for pandemic and seasonal influenza A. This randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability, viral and clinical measurements of healthy subjects infected with the influenza A virus dosed with oral CC-42344 treatment. Management determined that the low infectivity obtained in this study hindered antiviral data analysis. A dispute has arisen with the United Kingdom clinical research organization (the "CRO") that performed the Phase 2a study. The Company contends that the CRO breached its agreement in a number of respects and is requesting that the CRO refund the $6,309,000 it was paid or redo the study."
"As of the date of this Report, it appears that the Company will seek to arbitrate the dispute as required under the agreement with the CRO".
This is a nanocap biotech and they are probably lying to claim the money back, personally I'm not worried about this and it will be very hard to prove in court. Still holding.